The nervous system, estrogen and osteoporosis.
Completed
- Conditions
- osteoporosis, osteoporose
- Registration Number
- NL-OMON25589
- Lead Sponsor
- Academic Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 32
Inclusion Criteria
1. Female sex;
2. Last menstrual cycle 12-60 months ago.
Exclusion Criteria
1. Contraindications to HRT, beta-agonist or beta-antagonist treatment, such as cardiovascular disease, astma, COPD, renal or hepatic insufficiency;
2. Any medication or disease influencing bone turnover;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main study parameter is the difference in change of serum concentrations of bone turnover markers (procollagen type I N propeptide (P1NP) and C-terminal crosslinking telopeptides of collagen type I (CTX)) compared in the treatment and control groups.
- Secondary Outcome Measures
Name Time Method A secondary parameter is the change in number of circulating stem cells and osteogenic cells.